30
Participants
Start Date
March 31, 2005
Primary Completion Date
April 30, 2011
Study Completion Date
April 30, 2011
combination of gemcitabine, capecitabine, and bevacizumab
gemcitabine 1000 mg/m\^2 d1, 8, capecitabine 1000 mg (flat dose) po bid d1-14, and bevacizumab 15 mg/kg d 1, on a 21 day cycle
University of Chicago, Chicago
Collaborators (1)
Genentech, Inc.
INDUSTRY
Eli Lilly and Company
INDUSTRY
University of Chicago
OTHER